http://www.has-sante.fr/portail/jcms/c_1294166/vantas-histreline-en-implant-analogue-de-la-lh-rh http://www.has-sante.fr/portail/jcms/c_1294076/vantas-synthese-29022012 http://www.has-sante.fr/portail/jcms/c_1234448/vantas-29022012-avis-ct11421 2012 false France French guidelines for drug use evaluation of the transparency committee gonadotropin-releasing hormone histrelin Supprelin histrelin Supprelin drug implants antineoplastic agents antineoplastic agents neoplasms, hormone-dependent prostatic neoplasms late insurance, health, reimbursement palliative care injections, subcutaneous clinical trials, phase ii as topic clinical trials, phase iii as topic treatment outcome testosterone histrelin